STOCKHOLM, SWEDEN April 13, 2023. Karolinska Development AB today announces that its portfolio company AnaCardio has included the first patient in the company’s clinical phase 1b/2a study of. | April 13, 2023
STOCKHOLM, SWEDEN April 13, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has included the.
The shareholders of Karolinska Development AB , reg. no. 556707-5048, are invited to the Annual General Meeting, on Tuesday May 16, 2023, at 3:00 p.m. , at Life City, Solnavägen 3, SE-113. | April 11, 2023
STOCKHOLM, SWEDEN – March 28, 2023. Karolinska Development AB today announces that the portfolio company Umecrine Cognition has secured additional funding for the continued development of the. | March 28, 2023